Table 2 Efficacy of AI and clinical outcome
From: Efficacy of first-line doxorubicin and ifosfamide in myxoid liposarcoma
| Â | Resectable tumor No. (%) | Advanced disease No. (%) | Total No. (%) | P value |
|---|---|---|---|---|
Response by RECIST | Â | Â | Â | 0.48 |
PR | 10 (38.5) | 6 (54.5) | 16 (43.2%) | Â |
SD | 16 (61.5) | 5 (45.5) | 21 (56.8%) | Â |
Response by Choi criteria | Â | Â | Â | 1.00 |
PR | 22 (84.6) | 10 (91) | 32 (86.5%) | Â |
SD | 4 (15.4) | 1 (9) | 5 (13.5%) | Â |
Maximum % decrease in tumor size in cm, median (range) | 26.3 (6.2-56.1) | 29.9 (4.5-56.8) | 27.6% (4.5-56.8) | 0.5 |
Time to maximal response in months, median (range) | 4 (2-10) | 4 (3-7) | 4 (1.9-10.1) | 0.44 |
5-years DFS | 90% | Â | Â | (95% CI, 73.2 to 100) |
TTP in months, median | Â | 23 | Â | (95% CI, 9.01 to NA) |
OS in months, median | Â | 31.1 | Â | (95% CI, 20 to NA) |